The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The nineteenth annual DONNA Marathon Weekend concluded Sunday with greater than 9,700 runners registered in occasions throughout the First Coast. Athletes from...
The Nationwide Complete Most cancers Community (NCCN) has up to date its medical observe pointers to incorporate Trodelvy (sacituzumab govitecan-hziy) as a...
